{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:58:32Z","timestamp":1781074712631,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00228-026-04050-6","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:57:28Z","timestamp":1778731048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of the combination therapy of statin and dapagliflozin, a selective inhibitor of sodium_glucose Co-transporter type 2, in the treatment of Ischemic heart disease with heart failure: A randomized controlled trial"],"prefix":"10.1007","volume":"82","author":[{"given":"Asmaa M.","family":"Abdelkader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasnaa","family":"Osama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman S.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bshra A.","family":"Alsfouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanaa A.","family":"Elmasry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Elkhashab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghda R.S.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"4050_CR1","doi-asserted-by":"crossref","unstructured":"Zhang X, Wang Y, Li H, Wang DW, Chen C (2024) Insights into the post-translational modifications in heart failure. Ageing Res Rev. :102467","DOI":"10.1016\/j.arr.2024.102467"},{"issue":"31","key":"4050_CR2","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.2174\/1381612822666160701073452","volume":"22","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Doumas M, Mikhailidis P (2016) Lipids, statins and heart failure: an update. Curr Pharm Des 22(31):4796\u20134806","journal-title":"Curr Pharm Des"},{"issue":"4","key":"4050_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ccep.2015.08.001","volume":"7","author":"JA Mazurek","year":"2015","unstructured":"Mazurek JA, Jessup M (2015) Understanding heart failure. Cardiac Electrophysiol Clin 7(4):557\u2013575","journal-title":"Cardiac Electrophysiol Clin"},{"key":"4050_CR4","unstructured":"Novack M, Zubair M (2025) Natriuretic peptide B type test. StatPearls"},{"issue":"6","key":"4050_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","volume":"13","author":"B Ziaeian","year":"2016","unstructured":"Ziaeian B, Fonarow GC (2016) Epidemiology and aetiology of heart failure. Nat Rev Cardiol 13(6):368\u2013378","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"4050_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/j.2040-4603.2016.tb00669.x","volume":"6","author":"E Tanai","year":"2015","unstructured":"Tanai E, Frantz S (2015) Pathophysiology of heart failure. Compr Physiol 6(1):187\u2013214","journal-title":"Compr Physiol"},{"issue":"7","key":"4050_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5070062","volume":"5","author":"AA Inamdar","year":"2016","unstructured":"Inamdar AA, Inamdar AC (2016) Heart failure: diagnosis, management and utilization. J Clin Med 5(7):62","journal-title":"J Clin Med"},{"issue":"6","key":"4050_CR8","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.4103\/jfmpc.jfmpc_232_19","volume":"8","author":"A Pradhan","year":"2019","unstructured":"Pradhan A, Vohra S, Vishwakarma P, Sethi R (2019) Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure. J Family Med Prim Care 8(6):1855\u20131862","journal-title":"J Family Med Prim Care"},{"issue":"11","key":"4050_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115863","volume":"22","author":"G Palmiero","year":"2021","unstructured":"Palmiero G, Cesaro A, Vetrano E, Pafundi PC, Galiero R, Caturano A et al (2021) Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. Int J Mol Sci 22(11):5863","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4050_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamacardio.2021.0379","volume":"6","author":"JH Butt","year":"2021","unstructured":"Butt JH, Docherty KF, Petrie MC, Schou M, Kosiborod MN, O\u2019Meara E et al (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial. JAMA Cardiol 6(6):678\u201389","journal-title":"JAMA Cardiol"},{"issue":"12","key":"4050_CR11","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089\u20131098","journal-title":"N Engl J Med"},{"issue":"2","key":"4050_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jacl.2017.01.018","volume":"11","author":"HE Bays","year":"2017","unstructured":"Bays HE, Sartipy P, Xu J, Sj\u00f6str\u00f6m CD, Underberg JA (2017) Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. J Clin Lipidol 11(2):450\u2013458e1","journal-title":"J Clin Lipidol"},{"issue":"6","key":"4050_CR13","first-page":"631","volume":"32","author":"S Ramkumar","year":"2016","unstructured":"Ramkumar S, Raghunath A, Raghunath S (2016) Statin therapy: review of safety and potential side effects. Acta Cardiol Sin 32(6):631\u2013639","journal-title":"Acta Cardiol Sin"},{"issue":"5","key":"4050_CR14","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1161\/CIRCHEARTFAILURE.115.002143","volume":"8","author":"U Alehagen","year":"2015","unstructured":"Alehagen U, Benson L, Edner M, Dahlstr\u00f6m U, Lund LH (2015) Association between use of statins and mortality in patients with heart failure and ejection fraction of \u2265 50%. Circ Heart Fail 8(5):862\u2013870","journal-title":"Circ Heart Fail"},{"issue":"12","key":"4050_CR15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","volume":"15","author":"BB Adhyaru","year":"2018","unstructured":"Adhyaru BB, Jacobson TA (2018) Safety and efficacy of statin therapy. Nat Rev Cardiol 15(12):757\u2013769","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"4050_CR16","volume":"2","author":"JL Anderson","year":"2023","unstructured":"Anderson JL, May HT, Le VT, Muhlestein JB, Horne BD, Bair TL et al (2023) Impact of statin therapy in heart failure patients: results of a large real-world experience. JACC: Advances 2(4):100385","journal-title":"JACC: Advances"},{"issue":"1","key":"4050_CR17","first-page":"30","volume":"15","author":"M Niazi","year":"2020","unstructured":"Niazi M, Galehdar N, Jamshidi M, Mohammadi R, Moayyedkazemi A (2020) A review of the role of statins in heart failure treatment. Curr Clin Pharmacol 15(1):30\u201337","journal-title":"Curr Clin Pharmacol"},{"issue":"3","key":"4050_CR18","first-page":"14","volume":"81","author":"World Medical Association Declaration of Helsinki","year":"2014","unstructured":"World Medical Association Declaration of Helsinki (2014) : ethical principles for medical research involving human subjects. J Am Coll Dent 81(3):14\u201318","journal-title":"J Am Coll Dent"},{"issue":"11","key":"4050_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4663","volume":"33","author":"BCL Dias","year":"2019","unstructured":"Dias BCL, Fachi MM, de Campos ML, Degaut FLD, Peccinini RG, Pontarolo R (2019) A new HPLC\u2013MS\/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. Biomed Chromatogr 33(11):e4663","journal-title":"Biomed Chromatogr"},{"issue":"10","key":"4050_CR20","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1039\/c0ay00337a","volume":"2","author":"N Sultana","year":"2010","unstructured":"Sultana N, Arayne MS, Shafi N, Siddiqui FA, Hussain A (2010) Development of a RP-HPLC method for the simultaneous analysis of diltiazem and statin: application in pharmaceuticals and human serum. Anal Methods 2(10):1571\u20131576","journal-title":"Anal Methods"},{"issue":"1","key":"4050_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0529-3","volume":"16","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Zatti G, Vitturi N, Iori E, Marescotti MC et al (2017) Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol 16(1):42","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"4050_CR22","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u201328","journal-title":"N Engl J Med"},{"issue":"4","key":"4050_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u201357","journal-title":"N Engl J Med"},{"issue":"10","key":"4050_CR24","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61(10):2108\u20132117","journal-title":"Diabetologia"},{"issue":"21","key":"4050_CR25","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"issue":"10254","key":"4050_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396(10254):819\u201329","journal-title":"Lancet"},{"issue":"22","key":"4050_CR27","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RH et al (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139(22):2528\u201336","journal-title":"Circulation"},{"issue":"2","key":"4050_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/clc.20821","volume":"34","author":"L Zhang","year":"2011","unstructured":"Zhang L, Zhang S, Jiang H, Sun A, Zou Y, Ge J (2011) Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol 34(2):117\u2013123","journal-title":"Clin Cardiol"},{"key":"4050_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-017-0658-8","volume":"17","author":"T Sato","year":"2018","unstructured":"Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S et al (2018) The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol 17:1\u20139","journal-title":"Cardiovasc Diabetol"},{"key":"4050_CR30","unstructured":"Inamadar SS, Agrawal V, Naidu S, Sethi BK, Abstract No (2023) ABS003 Comparison of the effects of dapagliflozin versus metformin in overweight and obese non-diabetic PCOS women\u2013An interventional study"},{"issue":"6","key":"4050_CR31","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/oby.22798","volume":"28","author":"G Iacobellis","year":"2020","unstructured":"Iacobellis G, Gra-Menendez S (2020) Effects of dapagliflozin on epicardial fat thickness in patients with type 2 diabetes and obesity. Obesity 28(6):1068\u20131074","journal-title":"Obesity"},{"issue":"1","key":"4050_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.33899\/iphr.2023.137946.1041","volume":"20","author":"G Ahmed","year":"2023","unstructured":"Ahmed G, Abed M, Alassaf F (2023) An overview of the effects of Sodium-glucose Cotransporter-2 inhibitors on hematological parameters in diabetic patients. Iraqi J Pharm 20(1):65\u201371","journal-title":"Iraqi J Pharm"},{"issue":"9","key":"4050_CR33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/bph.13741","volume":"174","author":"A \u00c5strand","year":"2017","unstructured":"\u00c5strand A, Wingren C, Benjamin A, Tregoning JS, Garnett JP, Groves H et al (2017) Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice. Br J Pharmacol 174(9):836\u201347","journal-title":"Br J Pharmacol"},{"issue":"5","key":"4050_CR34","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.5114\/aoms\/158546","volume":"19","author":"S Chamani","year":"2023","unstructured":"Chamani S, Kooshkaki O, Moossavi M, Rastegar M, Soflaei SS, McCloskey AP et al (2023) The effects of statins on the function and differentiation of blood cells. Arch Med Sci 19(5):1314\u20131326","journal-title":"Arch Med Sci"},{"key":"4050_CR35","doi-asserted-by":"crossref","unstructured":"Gangat N, Tefferi A (2023) Sodium\u2013glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology. Oxford University Press, pp 2670\u20132672","DOI":"10.1093\/ndt\/gfad171"},{"key":"4050_CR36","doi-asserted-by":"crossref","unstructured":"Son M, Lee YS, Hong AR, Yoon JH, Kim HK, Kang H-C et al (2022) Improved Erythrocyte Deformability Induced by Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients. Cardiovasc Drugs Ther. :1\u20139","DOI":"10.1007\/s10557-020-07067-w"},{"issue":"17","key":"4050_CR37","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1001\/jama.296.17.2105","volume":"296","author":"AS Go","year":"2006","unstructured":"Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH (2006) Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296(17):2105\u20132111","journal-title":"JAMA"},{"key":"4050_CR38","doi-asserted-by":"crossref","unstructured":"investigators G-H. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. (2008) ;372(9645):1231\u20131239","DOI":"10.1016\/S0140-6736(08)61240-4"},{"issue":"8","key":"4050_CR39","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamainternmed.2016.2751","volume":"176","author":"M Leibowitz","year":"2016","unstructured":"Leibowitz M, Karpati T, Cohen-Stavi CJ, Feldman BS, Hoshen M, Bitterman H et al (2016) Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment. JAMA Intern Med 176(8):1105\u201313","journal-title":"JAMA Intern Med"},{"issue":"21","key":"4050_CR40","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.3390\/jcm11216544","volume":"11","author":"H Yaribeygi","year":"2022","unstructured":"Yaribeygi H, Maleki M, Reiner \u017d, Jamialahmadi T, Sahebkar A (2022) Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu. J Clin Med 11(21):6544","journal-title":"J Clin Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04050-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:17:38Z","timestamp":1781072258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04050-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4050"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04050-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4th author affiliation correction","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was secured from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}},{"value":"After assessing the study protocol for ethical and academic concerns, the Institutional Review Board of the Faculty of Medicine, Fayoum University, made the necessary amendments and granted approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}